L-PGDS Quantification in Genital, Blood, and Urine Samples From Adenomyosis Patients Compared to Two Control Groups

What this Trial Is About

Researchers are studying adenomyosis, a condition linked to excess estrogen causing chronic inflammation that leads to the growth of endometrial cells in the uterus muscle. This research focuses on Lipocalin type-prostaglandin D synthase (L-PGDS), a protein that may help diagnose adenomyosis early through blood or urine tests. The study compares L-PGDS levels in women with adenomyosis, women with other uterine pathologies, and healthy controls to better understand its role and potential as a diagnostic marker. Participants are grouped into those with adenomyosis, those with other uterine conditions, and healthy controls. The study collects samples including vaginal swabs, blood, urine, and tissue from endometrial ablation during surgery. The procedure involves injecting saline into the uterus to collect samples. The study measures L-PGDS concentrations in these samples on the day of collection and again in blood and urine after 6 to 8 weeks. During the study, participants will undergo endovaginal ultrasound or hysterectomy as clinically indicated. Researchers assess L-PGDS levels in various samples and grade adenomyosis severity. The study monitors participants for up to seven weeks and records clinical and imaging data. This observational study lasts from initial sample collection to follow-up evaluations, aiming to improve adenomyosis diagnosis using minimally invasive methods.

Determination of Lipocalin Type-prostaglandin (L-PGDS) in Blood, Urine, Vaginal Samples and Endometrial Ablation by Enzyme-linked Immunosorbent Assay